Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the most notable here.

Investor interest in Sanofi’s agreement with Ventyx ratcheted up last month when the French drugmaker bought Vigil Neuroscience.

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...

AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology ...

Gabriel House had seen better days. But for residents and their families, it was the center of a caring community. The ...

--Sanofi today announced it has awarded over $1 million in grants through its inaugural Healthy Futures Solution Fund to support local nonprofits across Massachusetts that are advancing community ...

Sanofi successfully prices €1.5 billion bond issue. Paris, June 17, 2025- Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:. About ...

American depositary receipts of Adagene rose 15% in premarket trading following an investment from Sanofi. ADRs were trading around $2.24. The stock is down 2% on the year. Sanofi agreed to invest ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations ...

The US Food and Drug Administration(FDA) has granted Fast Track designation to two non-mRNA combination vaccine candidates put forward by Sanofi.